Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes

Antimicrob Agents Chemother. 2011 Nov;55(11):5362-6. doi: 10.1128/AAC.00611-11. Epub 2011 Aug 8.

Abstract

Genotypes of samples from protease inhibitor-naïve patients in Frankfurt's HIV Cohort were analyzed with five tipranavir resistance prediction algorithms. Mean scores were higher in non-B than in B subtypes. The proportion of non-B subtypes increased with increasing scores, except in weighted algorithms. Virtual and in vitro phenotype analyses of samples with increased scores showed no reduced tipranavir susceptibility. Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than "natural resistance."

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Viral / genetics*
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Mutation
  • Pyridines / therapeutic use*
  • Pyrones / therapeutic use*
  • Sulfonamides

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Pyridines
  • Pyrones
  • Sulfonamides
  • tipranavir